Q-omics provides the consensus-scored USH2A profile across patient tissues and cancer cell-line models. USH2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, USH2A is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, USH2A RNA expression shows 17,675 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, THCA, and TGCT as cancer lineages where USH2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USH2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USH2A survival associations across molecular data types. USH2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USH2A RNA expression–survival associations across cancer types. High USH2A expression shows unfavorable associations in ACC, KIRC, LGG, UCS and KIRP, but favorable associations in SCLC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for USH2A RNA expression.
This table summarizes USH2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for USH2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USH2A shows lower tumor expression in THCA, KICH, CHOL, KIRP and LIHC and higher tumor expression in COAD. The THCA box plot shows higher USH2A RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p < 0.001).
This table shows molecular features associated with USH2A in patient tissues and cancer cell lines. In patient samples, USH2A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, USH2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
